Methodological issues related to antifungal drug interaction modelling for filamentous fungi

Reviews and Research in Medical Microbiology

Volumn 13, Issue 3, 2002, Pages 101-117

  Meletiadis, Joseph ^a   Meis, Jacques F G M ^a   Mouton, Johan W ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bliss independence; Colorimetric assays; Combination of antifungal drugs; FIC index; Filamentous fungi; In vitro antifungal susceptibility testing; Loewe additivity; Tetrazolium salts; Three dimensional analysis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; ITRACONAZOLE; NIKKOMYCIN; POSACONAZOLE; TERBINAFINE; TETRAZOLIUM; VORICONAZOLE;

ARTICLE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FUNGUS GROWTH; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOULD; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0036637224     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200207000-00002     Document Type: Article

References (102)

1. Brief review of fungal infections
2. Fungi as human pathogens
3. Epidemiology of invasive fungal infections in bone marrow transplantation
4. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
5. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
6. Invasive aspergillosis in transplant recipients
7. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review
8. The new fungal opportunists are coming
9. Epidemiology of nosocomial fungal infections
10. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management
11. Fungal infections in neutropenia: Current problems and chemotherapeutic control
12. Future directions of antifungal chemotherapy
13. The future of antifungal therapy
14. Investigational antifungal agents
15. Antifungal agents in the 1990s. Current status and future developments
16. Practice guidelines for the treatment of tuberculosis
17. The past, present and future of antimycotic combination therapy
18. Detecting drug interactions: A review of the literature
19. Epidemiology of drug-drug interactions as a cause of hospital admissions
20. Experimental models in antifungal chemotherapy
21. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
22. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics
23. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
24. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species
25. Synergy, additivism and antagonism in immunosuppression. A critical review
26. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: An E-test-based strategy
27. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
28. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro
29. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus
30. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: Demonstration of in vitro synergy between rifabutin and amphotericin B
31. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373
32. Combination of amorolfine with various antifungal drugs in dermatophytosis
33. Antimicrobial susceptibility testing
34. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
35. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi
36. Standardization of antifungal susceptibility testing and clinical relevance
37. Effect of inoculum form on in vitro antifungal susceptibilities of Aspergillus spp
38. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method
39. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
40. Present status of the detection of antifungal resistance: The perspective from both sides of the ocean
41. Antifungal drug resistance in Aspergillus
42. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi
43. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi
44. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans
45. Susceptibility testing of pathogenic fungi with itraconazole: A process analysis of test variables
46. Effects of incubation temperature, inoculum size, and time of reading on broth microdilution susceptibility test results for amphotericin B against Fusarium
47. Analysis of growth characteristics of filamentous fungi in different nutrient media
48. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
49. Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods
50. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
51. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection
52. Detection of amphotericin B-resistant Candida isolates in a broth-based system
53. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
54. Antifungal susceptibility testing
55. Antifungal susceptibility testing: Practical aspects and current challenges
56. Standardization of antifungal susceptibility testing
57. Tetrazolium salts and formazans
58. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
59. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates
60. The microculture tetrazolium assay (MTA): Another colorimetric method of testing Plasmodium falciparum chemosensitivity
61. Evaluation of MIDITECH automated colorimetric MIC reading for antimicrobial susceptibility testing
62. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl] -2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents
63. Comparison of NCCLS and 3-(4,5-dimethyl-2Thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
64. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species
65. Colorimetric assay for antifungal susceptibility testing of Aspergillus species
66. Clinical significance of interactions with antifungal agents
67. Drug interactions with itraconazole, fluconazole, and terbinafine and their management
68. Clinical effects of interaction between drugs. Review of points at which drugs can interact
69. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
70. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
71. Criteria for analyzing interactions between biologically active agents
72. What is synergy?
73. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higherorder kinetic systems with two or more mutually exclusive and nonexclusive inhibitors
74. Quantitative analysis of doseeffect relationships: The combined effects of multiple drugs or enzyme inhibitors
75. The search for synergy: A critical review from a response surface perspective
76. Antimicrobial combinations
77. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and-resistant Aspergillus fumigatus isolates
78. Role of pharmacokinetics in the outcome of infections
79. Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents
80. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine
81. A three-dimensional model to analyze drug-drug interactions
82. Drug combinations-concepts and terminology
83. Relating isobolograms to response surfaces
84. Isobolographic characterization of drug interactions incorporating biological variability
85. Review of the application of response surface methodology in the combination therapy of cancer
86. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine
87. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
88. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
89. Application of a new approach for the quantitation of drug synergism to the combination of cis-diammmedichloroplatinum and 1-beta-D-arabinofuranosylcytosine
90. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents
91. Susceptibility testing of fungi and correlation with clinical outcome
92. Clinical utility of in vitro antifungal susceptibility testing
93. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
94. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi
95. Antifungal pharmacodynamics: Review of the literature and clinical applications
96. In vitro models, in vivo models, and pharmacokinetics: What can we learn from in vitro models?
97. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir
98. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men